Created at	Source	Raw Value	Validated value
Jan. 5, 2022, 7 a.m.	usa	Change in geometric mean concentration (GMC) for S1 binding IgG antibodies from baseline to 14 days after the second injection;Change in geometric mean concentration (GMC) for S1 binding IgG antibodies from baseline to 21 days after the first injection;Incidence of solicited adverse events;Incidence of unsolicited adverse events;Percentage of participants with seroconversion for S1 binding IgG antibodies after the first injection;Percentage of participants with seroconversion for S1 binding IgG antibodies after the second injection	Change in geometric mean concentration (GMC) for S1 binding IgG antibodies from baseline to 14 days after the second injection;Change in geometric mean concentration (GMC) for S1 binding IgG antibodies from baseline to 21 days after the first injection;Incidence of solicited adverse events;Incidence of unsolicited adverse events;Percentage of participants with seroconversion for S1 binding IgG antibodies after the first injection;Percentage of participants with seroconversion for S1 binding IgG antibodies after the second injection
July 14, 2021, 6 a.m.	usa	Change in geometric mean concentration (GMC) for S-protein binding IgG antibodies from baseline to 14 days after the second injection;Change in geometric mean concentration (GMC) for S-protein binding IgG antibodies from baseline to 21 days after the first injection;Incidence of solicited adverse events;Incidence of unsolicited adverse events;Percentage of participants with seroconversion for S-protein binding IgG antibodies after the first injection;Percentage of participants with seroconversion for S-protein binding IgG antibodies after the second injection	Change in geometric mean concentration (GMC) for S-protein binding IgG antibodies from baseline to 14 days after the second injection;Change in geometric mean concentration (GMC) for S-protein binding IgG antibodies from baseline to 21 days after the first injection;Incidence of solicited adverse events;Incidence of unsolicited adverse events;Percentage of participants with seroconversion for S-protein binding IgG antibodies after the first injection;Percentage of participants with seroconversion for S-protein binding IgG antibodies after the second injection
July 1, 2021, 2:30 a.m.	usa	Change in geometric mean titer (GMT) for S-protein binding IgG antibodies from baseline to 14 days after the second injection;Change in geometric mean titer (GMT) for S-protein binding IgG antibodies from baseline to 21 days after the first injection;Incidence of solicited adverse events;Incidence of unsolicited adverse events;Percentage of participants with seroconversion for S-protein binding IgG antibodies after the first injection;Percentage of participants with seroconversion for S-protein binding IgG antibodies after the second injection	Change in geometric mean titer (GMT) for S-protein binding IgG antibodies from baseline to 14 days after the second injection;Change in geometric mean titer (GMT) for S-protein binding IgG antibodies from baseline to 21 days after the first injection;Incidence of solicited adverse events;Incidence of unsolicited adverse events;Percentage of participants with seroconversion for S-protein binding IgG antibodies after the first injection;Percentage of participants with seroconversion for S-protein binding IgG antibodies after the second injection